Please give info on why Adam is wrong about this point. Also I was a holder of Imcl, and FDA prevented Erbitux from going forward, at first, because it couldn't explain what had caused the Rash in positive responders. Hopefully I am comparing apples to oranges. Thanks, in advance.
For starters: 100 year safety record, outstanding efficacy in phase II trials, dual MoA, local and systemic benefits, bystander effect, promising results on multiple indications,strong potential as part of combination therapies (orthogonailty and safety).
I suggest you start DD with the company website (watch some of the research videos), the "connecting the dots..." PVCT blogsite, their is also a new blogsite of chosen yahoo posts - check the posts here of eckgar1.
Of course you should look at the papers from the researchers cited by ca_observer below.
I have not hear that Adam addressed any of the above points.
AF calls PVCT's drug #$%$". Mmmmm let me see, Moffitt Cancer cancer disagrees. Dr Thompson a world renound MM oncologist disagrees. Dr Merrik Ross disagrees. Dr Aggarawala disagrees. Obviously FDA disagrees (otherwise why would they not only allow a compassionate program for many years but also allow a doubling of the dose of the compassionate program) etc etc. Now it may be that some place AF's views ahead of these....
What point? This is AF your talking about. Do you really think that just because he writes for thestreet he has some real cred in bio-tech. All's he does is throws #$%$ up against the wall and see's if it sticks.. when it does somehow that give him cred? Do your own DD on the company